Neurocrine Biosciences is buying Soleno Therapeutics in a deal that hands Neurocrine the first FDA-approved drug for Prader-Willi syndrome, a rare disorder marked by relentless hunger. The agreement, valued at about $2.9 billion, centers on Vykat XR and changes the competitive landscape for rare-disease treatments. This move ties immediate commercial revenue to a long-term strategic push into rare conditions.
Under the terms announced, Neurocrine will pay $53 a share in cash, a roughly 34% premium to Soleno’s recent close. The company said it will fund the purchase mostly from cash on hand and take on some new debt to complete the financing. The deal is expected to wrap up by early July, subject to customary approvals.
Prader-Willi syndrome affects an estimated 10,000 people in the United States and is characterized by compulsive, unrelenting hunger that can lead to severe obesity, diabetes and even life-threatening complications like stomach rupture. Until Vykat XR reached the market, caretakers and clinicians had virtually no drug options specifically approved to address the syndrome’s core symptom. The human cost of the condition has long driven interest in therapies that can change patients’ daily realities.
Vykat XR secured FDA approval in March 2025 as the first and only treatment for Prader-Willi syndrome and generated roughly $190 million in its first year on the market. Those early sales figures give Neurocrine an immediate revenue stream to bolster its portfolio. For a mid-sized biotech, adding a newly approved, revenue-generating product is a meaningful step toward diversifying its earnings.
Market reaction was brisk: Soleno shares jumped more than 30% in morning trading while Neurocrine’s stock ticked down about 1.5%. Neurocrine’s chief executive, Kyle Gano, said management will leverage “our experience and capabilities to expand VYKAT XR’s reach to benefit more patients.” That line underscores the company’s public pitch—use commercial muscle to scale access and uptake.
For Neurocrine, the acquisition brings a third marketed medicine to a commercial slate led by Ingrezza, which produced $2.51 billion in revenue last year. The company has been beefing up its rare-disease footprint since late 2024, when approval of Crenessity—targeting an adrenal hormone disorder—contributed about $301 million in sales. Adding Vykat XR slots into a broader plan to balance one-off blockbusters with steady specialty franchises.
Neurocrine notes that Vykat XR’s patent estate should protect the product from direct competition until the mid-2040s, giving the company a long runway to establish payor relationships and scale production. That longevity matters to investors and to families who rely on consistent supply and coverage for chronic treatments. With exclusivity, the focus shifts from defending market share to expanding the pool of treated patients.
The deal also reflects a hot dealmaking streak in biotech: companies and investors inked about $68.6 billion in mergers and acquisitions in the first quarter, according to industry data. Big and small firms are hunting for approved assets that reduce regulatory risk and deliver immediate cash flow. For buyers, snapping up late-stage or approved drugs can be a faster route to growth than waiting on clinical shots in the dark.
Beyond the balance sheet, the acquisition raises practical questions about access: how quickly Neurocrine can increase production, navigate payer negotiations and educate clinicians and caregivers about Vykat XR. Those are the nuts-and-bolts challenges that determine whether an approved drug becomes a widely used standard of care or remains underutilized. Investors and patient advocates will be watching implementation closely as the companies move toward closing the transaction.
